DXCM DexCom, Inc.
DXCM DexCom, Inc.
Healthcare · Medical Devices
Desk view
Market read
Scan convergence 2 scans as of 2026-10-16 2 bull converging
POC $72.55 · VWAP $71.00 · +9.8% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster EVP, Director + 1 other sold $1.1M, Sep 14–16
Coverage
3 watchlists
DXCM Price Structure
Loading timeframes…
Peers
Every watchlist DXCM belongs to, members best 30-day change first — DXCM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@healthcare-scan
@healthcare
@biotech-scan
Reported the quarter ending 2026-06-30: revenue $1.31B, diluted EPS $0.64, net income $249M (SEC filing). Across the print the stock moved +11.1% (close before → first close after).
full note →Against street estimates
How DXCM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
DXCM research tape
86 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.